|
CSL Behring is a biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products. Its line of therapies includes products for the treatment of bleeding disorders such as hemophilia and von Willebrand Disease; primary immune deficiencies (PIDD); hereditary angioedema; inherited respiratory disease; and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.〔http://cslbehring.com/about〕 CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma.〔http://cslplasma.com/about.htm〕 == Company Statistics== Parent Company: CSL Limited, (ASX:CSL), Melbourne, Australia Headquarters: King of Prussia, PA Employees: 14,000+〔http://cslbehring.com/about〕 Operations: In 30 countries CEO and Managing Director: Paul Perreault〔http://cslbehring.com/about/management-team.htm〕 R&D: Marburg, Germany; Bern, Switzerland; King of Prussia, Pennsylvania, USA; Tokyo, Japan; Broadmeadows and Parkville, Victoria, Australia. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「CSL Behring」の詳細全文を読む スポンサード リンク
|